BINDER GUIDE / 01

Binder Types, Chemistry & Coverage

Cholestyramine, charcoal, zeolite, clays, humic and fulvic acids, and other options serve different purposes. Compare mechanisms, toxin coverage, and combinations.

Just For The Health Of It · Vancouver, Washington

EXPLORE THE DETAILS
Different binders.
Different roles.
Prescription · Mineral · Carbon · Biological
BINDER GUIDE

Why cholestyramine became central

Cholestyramine has received considerable attention over the past two decades.

Originally developed as a cholesterol-lowering medication, cholestyramine is a positively charged anion-exchange resin. Think of it as molecular Velcro. Its permanent positive charge allows it to grab negatively charged molecules that are secreted into bile and travel through the intestinal tract. That includes bile acids, ochratoxin A (OTA), PFAS (“forever chemicals”), certain persistent organic pollutants, some inflammatory lipids, and other compounds moving through enterohepatic circulation.

LiverPackages toxins into bile
IntestineBile enters the gut
Binder capturesEliminated in stool

Without binding, reabsorption can return toxins to the bloodstream and liver.

Without a binder, fat-soluble toxins secreted in bile are reabsorbed in the intestine and recycled back to the liver — a loop that continues even after someone leaves a moldy building. A binder interrupts the loop in the gut, so the toxin leaves in the stool.

This is exactly why cholestyramine became the cornerstone of Dr. Ritchie Shoemaker’s original CIRS protocol. For patients with elevated OTA or significant exposure to persistent environmental chemicals such as PFAS, it remains one of the most effective tools currently available. Colesevelam (Welchol) works by the same anion-exchange mechanism — generally gentler on the gut, though also somewhat weaker.

Evidence-Based

Cholestyramine has the strongest evidence base of any binder discussed here. Animal studies show it binds ochratoxin A directly in the gut, lowers plasma OTA, increases fecal excretion, and reduces OTA-induced kidney damage.1,2 A 2024 human crossover trial found that 12 weeks of cholestyramine lowered serum PFOS by roughly 60%, with a related trial showing meaningful reductions using colesevelam as well.3,4 It also reduces the intestinal absorption and toxicity of bacterial endotoxin (LPS).8

BINDER GUIDE

Where cholestyramine falls short

Not every mycotoxin behaves like ochratoxin A. This is where many discussions become oversimplified.

Some mycotoxins are strongly acidic and negatively charged. Others are essentially neutral. Some are highly fat soluble; others are relatively polar. Some undergo extensive enterohepatic recirculation; others appear to undergo very little. If a toxin doesn’t recycle through bile, a bile-acid sequestrant may not be nearly as effective. And if a toxin carries little negative charge, a positively charged resin will have much less affinity for it.

That doesn’t mean cholestyramine “doesn’t work.” It simply means it probably isn’t the entire answer.

There is also a very practical problem. Many of the sickest patients cannot tolerate cholestyramine at first. It commonly causes constipation, bloating, and reflux, and it can bind medications, thyroid hormone, and fat-soluble vitamins (A, D, E, K) if not separated by several hours. For someone who already struggles with constipation, mast cell activation, or autonomic dysfunction, four scoops of a potent bile-acid sequestrant on day one can make them miserable.

BINDER GUIDE

Why patients can still improve on cholestyramine

The CIRS community treats cholestyramine as the binder of choice, yet the chemistry shows that CSM has little affinity for a great many mycotoxins — aflatoxins, most trichothecenes, gliotoxin, and others. So why do so many patients clearly improve on it?

Two proposed explanations help account for this. First, cholestyramine happens to be excellent at the toxins that matter most for the bile-recycling loop — ochratoxin A, PFAS, bile acids, and inflammatory or oxidized fats. Second, and probably more important, it is the strongest available interrupter of enterohepatic circulation. By breaking that reabsorption loop, it clears an entire class of bile-bound toxins at once — very likely including many that the research literature has not yet even characterized.

Clinical Perspective

This may be cholestyramine’s real superpower. Beyond ochratoxin A, it grabs bile acids, oxidized polyunsaturated fats (PUFAs) and inflammatory lipids, PFAS, and endotoxin (LPS) — and because it so powerfully interrupts enterohepatic recirculation, it is plausibly removing a range of bile-excreted toxins that simply haven’t been studied yet. The studies may just not have caught up to the clinical observation.

But the paradox cuts the other way too. Many patients do well at first and then stall — stuck on the Shoemaker protocol for many months or even years with no further progress. When that happens, it is usually a signal of one of two things: either exposure is ongoing, or the remaining burden is now dominated by mycotoxins and metals that cholestyramine simply does not bind well. That is precisely the moment when other binders — zeolite, clays, glucomannan, charcoal, humic and fulvic acids — earn their place. The answer to a stalled protocol is often not more cholestyramine, but a wider net.

BINDER GUIDE

Binder categories by chemistry

A useful way to organize binders is by how they work, rather than by brand. Once you see the underlying chemistry, the confusing landscape of competing products starts to make sense — and so does the rationale for combining them.

ChemistryRepresentative bindersHow it worksBest-supported targets
Anion exchangeCholestyramine, Colesevelam (Welchol)Permanent positive charge swaps chloride for negatively charged moleculesBile acids, ochratoxin A, PFAS, some persistent organic pollutants, LPS
Cation exchangeZeolite / ZeoCharge® (clinoptilolite)Negatively charged aluminosilicate lattice exchanges positive ions; microporous surface also adsorbsLead, cadmium, mercury (some forms), ammonium; some mycotoxins via adsorption
Surface adsorptionActivated charcoal, silicaEnormous surface area binds by hydrophobic and van der Waals forces, largely charge-indifferentBroad organic toxins, many drugs and bacterial metabolites
Clay adsorptionBentonite, montmorillonite, HSCASLayered clay surfaces trap molecules that fit their structureAflatoxins and some Fusarium toxins (strong veterinary data)
Biological adsorptionModified glucomannan (yeast cell wall), S. boulardii, spore-based probiotics (MegaSpore®)Hydrogen bonding and molecular fit; some microbes also biotransform toxins and support the gut barrierAflatoxins, zearalenone, several Fusarium toxins; gut-barrier & LPS support
Cationic polysaccharideChitosanPositively charged fiber that binds fats and bile, with some ionic and adsorptive toxin bindingDietary fat and bile acids, some heavy metals and PFAS, some mycotoxins
Humic / fulvicCarboxy®, humic and fulvic acidsMulti-mechanism: ionic attraction, chelation, hydrogen bonding, redox chemistryBroad environmental support; metal chelation; gut-barrier and antioxidant effects
Combination formulasGI Detox®, Ultra Binder®, BIND-GENIC®Blend several chemistries (charcoal, clays, silica, zeolite, humic substances)Broad-spectrum coverage across toxin classes

Think of this the way an infectious-disease physician thinks about antibiotics. You wouldn’t treat every infection with the single most powerful drug on the shelf. You match the agent to the organism, the tissue, and what the patient can tolerate. Binders deserve the same reasoning.

BINDER GUIDE

Zeolite & ZeoCharge®

ZeoCharge® is a purified clinoptilolite zeolite. Most clinicians think of zeolite simply as a heavy-metal binder — and to be fair, that is where much of its strongest evidence lies. Zeolites are negatively charged aluminosilicate minerals that excel at binding positively charged ions such as lead, cadmium, and ammonium. Human data support increased urinary excretion of several toxic metals with activated clinoptilolite.5,6

But the chemistry doesn’t stop there. Because zeolites have a remarkable internal surface area and a microporous crystal structure, they can also adsorb certain organic compounds — including some mycotoxins — through hydrogen bonding and van der Waals forces rather than simple ion exchange. In other words, zeolite does grab mold toxins. It simply does so less powerfully than cholestyramine does for a strongly negatively charged toxin like ochratoxin A.

Two distinctions matter. The first is claiming zeolite is a high-affinity OTA binder equal to CSM — the chemistry doesn’t support that. The second, and more common, is dismissing it as “heavy metals only.” The feed-science and veterinary literature clearly shows clinoptilolite adsorbing aflatoxins and other mycotoxins, even if it is inconsistent for trichothecenes.7,9

This is the clinical rationale for ZeoCharge as a broad starting binder. Most mold-exposed patients don’t have just one toxin — they carry a mixture of heavy metals, mycotoxins, ammonium, histamine, and other burdens. A binder that addresses several of those at once, while being gentle on the gut, is a sensible place to begin, especially when GI issues are present. A common clinical pairing is ZeoCharge with Carboxy® as a well-tolerated, broad-spectrum foundation, followed by stronger prescription binders as tolerance improves.

Emerging Research

The claim that zeolite adsorbs mycotoxins comes largely from in-vitro and animal feed studies, where clinoptilolite has bound >80% of aflatoxin B1 in some models and reduced aflatoxin M1 in dairy milk.7,9 Robust independent human trials showing that ZeoCharge lowers urine mycotoxins such as OTA or trichothecenes are not yet available. This is promising, mechanistically plausible, and consistent with clinical experience—not settled fact.

BINDER GUIDE

Humic & fulvic acids

Humic and fulvic acid blends such as Carboxy® deserve their own category. These compounds are chemically complex, carrying carboxyl groups, phenols, quinones, and aromatic rings that let them interact through ionic attraction, hydrogen bonding, hydrophobic interactions, metal chelation, and redox chemistry.

That versatility matters, because fulvic and humic acids are not just mold-toxin binders. Their diverse chemistry lets them engage a wide range of toxicants — heavy metals, pesticides and herbicides, and other environmental chemicals — which is exactly why they fit the broader “total toxic burden” picture. These can be viewed less as simple “sponges” and more as biologically active detoxification-support compounds that may chelate some metals, support antioxidant defenses and gut-barrier integrity, and influence the microbiome. The strongest human data are still limited, but they are usually very well tolerated, which makes them valuable for sensitive patients and a natural complement to ZeoCharge early in a program.

Do fulvic and humic acids actually do anything at the cellular level, or do they just sit in the gut? It is a fair challenge — and the laboratory evidence is more substantial than most people realize. In human cell lines and animal models, fulvic and humic acids show real biological activity. They lower inflammatory signaling (reducing TNF-α, COX-2, and NF-κB activation),22 they stabilize mast cells and reduce histamine release — even lowering intracellular calcium, which is directly relevant to the mast cell activation so many mold patients struggle with23 — they scavenge reactive oxygen species as antioxidants,25 and they even interfere with the tau-protein aggregation implicated in neurodegeneration.24 Chemically, their many reactive functional groups let them bind an unusually broad range of toxins: heavy metals, pesticides and glyphosate, and even PFAS.26,27 And formal toxicology work places their safety margin very high, with no adverse effects in animals even at large doses.21

Emerging Research

An honest caveat: most of this evidence comes from in-vitro (cell-culture) and animal studies. They establish that fulvic and humic acids are biologically active at the cellular and molecular level and bind a wide array of toxins — but robust human data on exactly how much is absorbed, and how deeply these compounds penetrate into tissues, is still limited. The cellular activity is compelling and consistent with clinical observations, while human pharmacokinetics are still being worked out.

Not every humic/fulvic product is equally strong. For very sensitive patients, an even gentler carbon-and-fulvic option such as CellCore’s Biotoxin Binder can be a useful starting point — it is generally not as potent as Carboxy, but some patients need to begin there and work up as tolerance improves.

BINDER GUIDE

Glucomannan, chitosan & probiotics

Glucomannan — the underappreciated one

Modified glucomannan, derived from the cell wall of Saccharomyces cerevisiae yeast, is one of the most overlooked binders in human environmental medicine — largely because most of its evidence lives in the veterinary and feed-science literature. There it is impressive. Esterified glucomannan has bound roughly 75–90% of aflatoxin in vitro and meaningfully protected animals from aflatoxin, zearalenone, and several Fusarium toxins. It works not through charge but through hydrogen bonding, molecular fit, and hydrophobic interaction, which is why it can grab neutral toxins that anion-exchange resins largely miss. It is also very well tolerated, which makes it a useful addition for patients who need broader coverage.

Chitosan — a positively charged fiber

Chitosan is a cationic polysaccharide made from the shells of crustaceans. Its positive charge lets it bind dietary fats and bile, along with some heavy metals, PFAS, and certain mycotoxins. Because it reduces fat absorption, timing and dosing matter, and anyone with a shellfish allergy should avoid it. Chitosan is considered a niche tool rather than a first-line binder — useful in specific situations, particularly where fat-soluble toxin recycling and lipid handling overlap.

MegaSpore® and spore-based probiotics

This may be the most surprising entry on the list. Spore-based probiotics such as MegaSpore® (a blend of Bacillus strains) are not “binders” in the classic adsorptive sense, yet they earn a place in the conversation for two reasons. First, certain probiotic strains can physically bind or biologically transform a range of mycotoxins in the gut — which is why “probiotics” light up across so many rows on binder charts. Second, and arguably more important, they strengthen the intestinal barrier, help calm endotoxin (LPS) load, and support healthier bile flow and motility. In other words, they help the terrain that determines whether every other binder can do its job. These are often used alongside binders rather than in place of them.

BINDER GUIDE

The range of mold-related markers

Read the range of mold-related markers

Early binder discussions tended to focus on just a handful of mycotoxins. Modern serum (IgG/IgE) and urine panels are far broader. One serum antibody panel used clinically, for example, screens up to fourteen mold-related markers — and each behaves differently, which is exactly why binder selection has to be individualized.

Trichothecenes

Satratoxin

A highly potent macrocyclic trichothecene, mainly from Stachybotrys (“black mold”).

Trichothecenes

Verrucarin & Verrucarol

Macrocyclic trichothecenes, also largely from Stachybotrys.

Trichothecenes

Stachybotrys trichothecene

The broader trichothecene group produced by Stachybotrys.

Trichothecenes

T-2 toxin

A potent Fusarium trichothecene; notable for dermal and immune toxicity.

Trichothecenes

Deoxynivalenol (Vomitoxin / DON)

A common Fusarium trichothecene with prominent GI effects.

Aspergillus / Penicillium

Ochratoxin A (and B)

Nephrotoxic and immunotoxic; the classic cholestyramine target.

Aspergillus / Penicillium

Sterigmatocystin

A carcinogenic Aspergillus toxin and biochemical precursor to aflatoxin.

Aspergillus / Penicillium

Gliotoxin

Immunosuppressive and neurotoxic; from Aspergillus and Penicillium.

Aspergillus / Penicillium

Mycophenolic acid

An immunosuppressive Penicillium toxin.

Aspergillus

Aspergillus hemolysin

An Aspergillus antigen/hemolytic protein marking exposure (not a classic small-molecule toxin).

Fusarium

Fumonisin B1

A Fusarium toxin affecting the nervous system and organs.

Fusarium

Zearalenone (ZEA)

An estrogenic Fusarium toxin with hormonal effects.

Alternaria

Alternariol

The signature mycotoxin of Alternaria mold.

Cladosporium

Cladosporium HSP70

A stress-protein marker of Cladosporium exposure rather than a classic toxin.

Different labs and panels cover different toxins — urine panels frequently add aflatoxins, citrinin, enniatins, and others. The point is not to memorize the list but to appreciate the diversity: with this many chemically distinct toxins in play, no single binder could possibly be ideal for all of them.

COMPARISON CHART

Precision biotoxin & binder chart

Binary “X” charts that simply mark whether a binder touches a toxin hide the most useful information: how strongly it binds. Below is a more granular version. Each cell rates the relative binding capacity of a binder for a specific biotoxin — mycotoxins plus actinomycetes, endotoxins, beta-glucans, and organic compounds — on a five-star scale, drawing on in-vitro data, the veterinary and feed-science literature, and clinical experience.

BiotoxinCholestyramine / WelcholActivated CharcoalClays (bentonite)Zeolite / ZeoCharge®GlucomannanChlorellaHumic / Fulvic (Carboxy®)ChitosanProbiotics (MegaSpore®)
Aflatoxins★★☆☆☆★★★★☆★★★★★★★★★☆★★★★☆★★☆☆☆★★☆☆☆★★☆☆☆★★★☆☆
Ochratoxin A (OTA)★★★★★★★★☆☆★★☆☆☆★★☆☆☆★★★☆☆★★☆☆☆★★★☆☆★★☆☆☆★★☆☆☆
Gliotoxinn/a★★☆☆☆★★★☆☆n/an/an/an/an/a★★☆☆☆
Sterigmatocystinn/a★★☆☆☆★★☆☆☆n/an/an/an/an/a★★☆☆☆
Macrocyclic trichothecenes (Stachybotrys)n/a★★★☆☆★★☆☆☆n/a★★☆☆☆n/an/an/a★★☆☆☆
Zearalenone (ZEA)★☆☆☆☆★★★☆☆★★★★☆★★★☆☆★★★★☆★★☆☆☆★★☆☆☆★★☆☆☆★★★☆☆
Enniatin Bn/a★★☆☆☆n/an/an/an/an/an/a★★☆☆☆
Citrinin★☆☆☆☆★★☆☆☆★★☆☆☆★★☆☆☆n/an/an/an/a★★☆☆☆
T-2 toxinn/a★★★☆☆★★☆☆☆★☆☆☆☆★★☆☆☆★☆☆☆☆★☆☆☆☆★☆☆☆☆★★☆☆☆
Deoxynivalenol (DON / vomitoxin)n/a★★☆☆☆★☆☆☆☆★☆☆☆☆★★☆☆☆★☆☆☆☆★☆☆☆☆★☆☆☆☆★★☆☆☆
Fumonisin B1★★★☆☆★★★☆☆★★★★☆★★☆☆☆★★★★☆★★☆☆☆★★☆☆☆★★☆☆☆★★★☆☆
Actinomycetes (actinobacteria)★★★☆☆★★★☆☆★★☆☆☆★★☆☆☆★☆☆☆☆★★☆☆☆★★☆☆☆★☆☆☆☆★★☆☆☆
Endotoxins (LPS)★★★★☆★★★☆☆★★☆☆☆★★☆☆☆★★☆☆☆★★☆☆☆★★☆☆☆★★☆☆☆★★★☆☆
Beta-glucansn/a★☆☆☆☆★☆☆☆☆n/an/an/a★☆☆☆☆★☆☆☆☆★☆☆☆☆
Volatile organics (VOCs)★☆☆☆☆★★★★☆★☆☆☆☆★★★☆☆n/a★☆☆☆☆★☆☆☆☆★☆☆☆☆n/a
Semi-volatile organics (SVOCs)★★☆☆☆★★★☆☆★★☆☆☆★★☆☆☆★☆☆☆☆★★☆☆☆★★☆☆☆★★☆☆☆★☆☆☆☆

How to read it: ★★★★★ = strongest, best-supported binding for that toxin · ★★★ = moderate · ★☆☆☆☆ = weak but plausible · n/a = little or no meaningful data. A blank or low rating usually means the binder hasn’t been well studied for that toxin — not that it has been proven useless.

Emerging Research

This chart is a clinical teaching tool, not a settled scientific consensus. Much of the strongest data comes from animal, feed-science, and in-vitro studies; robust human trials are limited for most binder–toxin pairs. Notice the pattern, though: no single binder wins every row. Cholestyramine dominates ochratoxin A, clays and glucomannan lead for aflatoxins and zearalenone, and activated charcoal spreads broadly across many toxins — which is exactly why thoughtful combinations tend to outperform any one product. The non-mycotoxin rows — actinomycetes, endotoxins, beta-glucans, and VOCs/SVOCs — are especially preliminary and lean heavily on chemical rationale and clinical experience rather than hard human data.

FUNCTIONAL MEDICINE / VANCOUVER, WA

Find a binder strategy
that fits.

The best binder is the one matched to your toxins, your gut, and your tolerance — and often it’s a thoughtful combination rather than a single product.

Just For The Health Of It
2402 Broadway Street
Vancouver, WA 98663

(360) 241-6630

Functional medicine intake ↗

CIRS & mold illness ↗

Sources & references
  1. Kerkadi A, et al. Dietary cholestyramine reduces ochratoxin A–induced nephrotoxicity in the rat by decreasing plasma levels and enhancing fecal excretion of the toxin. J Toxicol Environ Health. 1998. pubmed.ncbi.nlm.nih.gov/9482354
  2. Madhyastha S, et al. Cholestyramine protection against ochratoxin A toxicity: role of ochratoxin A sorption by the resin and bile acid enterohepatic circulation. J Food Prot. 1999. pubmed.ncbi.nlm.nih.gov/10606152
  3. Substantial decrease of PFAS with anion-exchange resin treatment — a clinical cross-over trial. Environ Int. 2024. pubmed.ncbi.nlm.nih.gov/38367552
  4. Serum, urinary and fecal PFAS after cholestyramine/colesevelam and probenecid — cross-over trials, Ronneby, Sweden. Environ Int. 2025. pubmed.ncbi.nlm.nih.gov/40974835
  5. Flowers JL, et al. Clinical evidence supporting the use of an activated clinoptilolite suspension to increase urinary excretion of toxic heavy metals. Nutr Diet Suppl. 2009. dovepress.com
  6. Kraljević Pavelić S, et al. Critical review on zeolite clinoptilolite safety and medical applications in vivo. Front Pharmacol. 2018. pmc.ncbi.nlm.nih.gov/PMC6277462
  7. Mycotoxin binding properties and in-vitro adsorption of aflatoxin B1 by clinoptilolite (feed-science literature review). pmc.ncbi.nlm.nih.gov/PMC9685567
  8. Effect of cholestyramine on endotoxin toxicity and absorption. Dig Dis Sci. doi.org/10.1007/BF02232738
  9. Katsoulos PD, et al. In-field evaluation of clinoptilolite feeding efficacy on the reduction of milk aflatoxin M1 concentration in dairy cattle. 2016. pubmed.ncbi.nlm.nih.gov/27413536
  10. Aravind KL, et al. Efficacy of esterified glucomannan (modified yeast cell wall) against aflatoxin, ochratoxin, and T-2 toxin in broilers (representative veterinary literature). researchgate.net/publication/263623090
  11. Aflatoxin B1–glutathione conjugation via glutathione-S-transferase as a major detoxification pathway (kinetic studies in liver and kidney). pubmed.ncbi.nlm.nih.gov/10854630
  12. Glutathione intensifies gliotoxin-induced cytotoxicity in human neuroblastoma (SH-SY5Y) cells. 2006. pubmed.ncbi.nlm.nih.gov/16525752
  13. Crista J. Break the Mold; “bioflavonoids before binders” and kidney-protective approach to mold recovery. drcrista.com
  14. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999. pubmed.ncbi.nlm.nih.gov/10334980
  15. Fungal (Candida) biofilm matrix reduces antifungal penetration and drives drug resistance. pmc.ncbi.nlm.nih.gov/PMC3299327
  16. Aflatoxin B1 is classified by IARC as a Group 1 human carcinogen; chronic exposure drives oxidative stress and liver injury (review). pmc.ncbi.nlm.nih.gov/PMC10386527
  17. Shoemaker RC, et al. HLA-DR haplotypes and susceptibility to biotoxin (CIRS) illness — roughly a quarter of the population clears mycotoxins poorly. survivingmold.com
  18. Shoemaker RC. Diagnosis of Pfiesteria–Human Illness Syndrome. Maryland Medical Journal. 1997 — the original description of cholestyramine for biotoxin illness. survivingmold.com
  19. Exposure to Actinobacteria resident in water-damaged buildings and resultant immune injury in CIRS; Streptomyces and related actinobacteria as potent inflammation inducers. Medical Research Archives. esmed.org/MRA
  20. A review of semi-volatile organic compounds (SVOCs) in the indoor environment: occurrence in consumer products, indoor air, and dust. Sci Total Environ. sciencedirect.com
  21. Murbach TS, et al. A toxicological evaluation of a fulvic and humic acids preparation (NOAEL 2000 mg/kg/day; no genotoxicity). Toxicology Reports. 2020;7:1242–1254. pmc.ncbi.nlm.nih.gov/PMC7505752
  22. Junek R, et al. Bimodal effect of humic acids on the LPS-induced TNF-α release from differentiated human U937 cells. Phytomedicine. 2009;16(5):470–476.
  23. Yamada P, et al. Inhibitory effect of fulvic acid on chemical-mediator (histamine) release by mast/basophil cells (RBL-2H3, KU812), with reduced intracellular Ca2+. Biosci Biotechnol Biochem. 2007;71(5):1294–1305. academic.oup.com
  24. Cornejo A, et al. Fulvic acid inhibits aggregation and promotes disassembly of tau fibrils associated with Alzheimer’s disease. J Alzheimers Dis. 2011;27(1):143–153. journals.sagepub.com
  25. Cárdenas-Rodríguez N, et al. Antioxidant activity of fulvic acid: a living-matter-derived bioactive compound (ROS scavenging). J Food Agric Environ. 2011;9(3&4):123–127.
  26. Chianese S, et al. Sorption of organic pollutants by humic acids: a review. Molecules. 2020;25(4):918. doi.org/10.3390/molecules25040918
  27. Qiang L, et al. Fulvic acid reduces bioaccumulation of perfluorooctane sulfonate (PFOS). Environ Sci Technol. 2016;50(21):11627–11636.
  28. Essential phospholipids (polyenylphosphatidylcholine) decrease apoptosis and increase membrane transport in human hepatocyte cell lines. Lipids Health Dis. 2022. pmc.ncbi.nlm.nih.gov/PMC9508738

Established evidence, mechanistically plausible hypotheses, and clinical experience are distinguished throughout these guides. Where the science is emerging—particularly for zeolite and mycotoxins—the limitations are included.

Educational disclaimer. This article is provided for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. Binders can interact with medications, supplements, vitamins, and minerals, and are not appropriate for everyone. Product names are referenced to illustrate categories of binder chemistry and do not represent an endorsement or a claim that any product treats or cures disease. Toxin binder therapy should always be individualized and supervised by a qualified healthcare professional. Please consult your provider before starting, stopping, or combining any binder.